Pharmaceutical Contract Manufacturing Global Market – Forecast To 2027

Publishing Date : May, 2021
Report Code : HCPH0113
Price:
Single license $5,400
Site license $7,200
Global license $9,000


Note: The report would be dispatched after confirmation of payment

 

Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing, and formulation due to rise in population, increase in chronic diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, mergers, and acquisitions. Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of well-equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).

The pharmaceutical contract manufacturing global market is expected to reach $120,124.7 million by 2027 growing at a high single digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth. The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography.

The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment accounted for the largest share in 2020 and FDF manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. The high profit margin for pharma contract manufacturers, shifting from API to FDF manufacturing by CMOs and CDMOs, rising demand for advanced dosage forms, and rising demand for generic drugs are some of the factors driving the growth of the FDF contract manufacturing market.

The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.

The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2020 due to changing consumer demands, advent and progress of newer dosage forms, and ever-evolving regulations. The injectable dosage form is the fastest-growing segment and is expected to grow at a low teen CAGR from 2020 to 2027 due to its direct infusion to the body, ease of administration, and onset of action of drugs is faster as compared to solid dosage forms. Hence it is suitable for emergency conditions. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of in 2020 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions.

The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue in 2020 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups.

Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the largest revenue in 2020 due to huge demand for commercial API production, patent expiry, and increasing outsourcing of generic APIs. Whereas, clinical manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027 owing to a rise in demand for effective novel drugs with various therapeutic applications, rise in R&D investments for discovering new drugs coupled with the rising number of different types of chronic diseases.

The pharmaceutical contract manufacturing market by therapeutic applications is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. Among these applications, the infectious disease segment accounted for the largest revenue in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is the fastest growing and is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and rising demand for personalized medicine especially for treating cancer.

The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2020. The developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing governments focus on generic drugs as well as the establishment of domestic API manufacturers, rising demands for the specialty of drugs and technological advancements, rising demand for advanced dosage forms, and also establishment of foreign CMOs/CDMOs are some of the factors driving the market growth. The Asia-Pacific region is the fastest growing region and is expected to grow at double digit CAGR from 2020 to 2027. Low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players, coupled with low investments for the establishment of manufacturing facilities as compared to western countries.

Some of the major players are Lonza Group (Switzerland), AbbVie Inc. (AbbVie contract manufacturing, U.S.), Thermo Fisher Scientific (Patheon, N.V., U.S.), Pfizer Inc. (Pfizer CentreOne, U.S.), Permira Funds (Cambrex Corporation, U.K.), Carlyle Group (Albany Molecular Research Inc. U.S.), WuXi AppTec (WuXi STA pharmaceuticals, China), Recipharm AB (publ) (Sweden), Aenova Group GmbH (Germany), China Resources Pharmaceutical Group Limited (China), and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific 
  • China
  • India
  • Japan
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     Increased trend of outsourcing
        • 3.3.1.2     High uptake of small molecules across diverse therapeutics
        • 3.3.1.3     Patent expiration of small molecules drugs
        • 3.3.1.4     Advanced technologies in API and FDF manufacturing
        • 3.3.1.5     Increasing deals and investments
        • 3.3.1.6     Generics drive injectable market opportunity
        • 3.3.1.7     Increasing chronic diseases
        • 3.3.1.8     Increase in geriatric population
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     Contamination in the manufacturing process (API and FDF)
        • 3.3.2.2     Pricing pressure for pharmaceutical contract manufacturing
        • 3.3.2.3     Requirement of highly skilled technicians
        • 3.3.2.4     Increasing biologics approvals and adoption in disease management
        • 3.3.2.5     Stringent regulatory requirements
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 Quality management system
        • 3.4.1.2     ISO 14644-1 Clean room standards
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     MEXICO
      • 3.4.5     EUROPE
      • 3.4.6     JAPAN
      • 3.4.7     CHINA
      • 3.4.8     INDIA
      • 3.4.9     AUSTRALIA
      • 3.4.10     SOUTH KOREA
      • 3.4.11     LATIN AMERICA
      • 3.4.12     MIDDLE EAST
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     BARGAINING POWER OF SUPPLIERS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     COMPETITIVE RIVALRY
    • 3.6     SUPPLY CHAIN ANALYSIS
    • 3.7     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.7.1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS
      • 3.7.2     MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR PLAYERS
      • 3.7.3     MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR PLAYERS
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     INTRODUCTION
      • 3.8.2     ADVANCED TECHNOLOGIES FOR API MANUFACTURING
      • 3.8.3     ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING
    • 3.9     DIFFERENTIATED CAPABILITIES
      • 3.9.1     HPAPI
        • 3.9.1.1     Selected top selling HPAPI
      • 3.9.2     CONTINUOUS FLOW MANUFACTURING
      • 3.9.3     CRYOGENIC MANUFACTURING PROCESS
    • 3.10     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
    • 3.11     PATENT EXPIRY AND ANDA APPROVALS
    • 3.12     DRUG MASTER FILING (DMF)
    • 3.13     COST OF MANUFACTURING FACILITY
    • 3.14     FDA APPROVED MANUFACTURING FACILITY
    • 3.15     FDA AND EMA APPROVAL DRUGS WITH TYPE OF DOSAGE FORM
    • 3.16     NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
    • 3.17     IMPACT OF CORONA ON PHARMACEUTICAL CONTRACT MANUFACTURING
    • 3.18     COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
    • 3.19     COMPANIES ACQUISITION, MERGER AND INVESTMENTS
    • 3.20     API PRICING
    • 3.21     GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
    • 3.22     CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
      • 3.22.1     INDIA
      • 3.22.2     CHINA
    • 3.23     PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE
  • 4     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     API MANUFACTURING
      • 4.2.1     BRANDED API MANUFACTURING
      • 4.2.2     GENERIC API MANUFACTURING
    • 4.3     FINISHED DOSAGE FORM (FDF) MANUFACTURING
      • 4.3.1     SOLID DOSAGE FORMS
        • 4.3.1.1     Tablets
        • 4.3.1.2     Capsules
        • 4.3.1.3     Other Solid Dosage Forms (Granules And Powders)
      • 4.3.2     INJECTABLES DOSAGE FORMS
      • 4.3.3     SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS
        • 4.3.3.1     Semisolids
        • 4.3.3.2     Liquids
        • 4.3.3.3     Gaseous
  • 5     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE
    • 5.1     INTRODUCTION
    • 5.2     CLINICAL MANUFACTURING
    • 5.3     COMMERCIAL MANUFACTURING
  • 6     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     ONCOLOGY
    • 6.3     CENTRAL NERVOUS SYSTEM
    • 6.4     CARDIOVASCULAR DISORDERS
    • 6.5     INFECTIOUS DISEASES
    • 6.6     PULMONARY DISORDERS
    • 6.7     METABOLIC DISORDERS
    • 6.8     GASTROINTESTINAL DISORDERS
    • 6.9     MUSCULOSKELETAL DISORDERS
    • 6.10     GENITOURINARY DISORDERS
    • 6.11     ENDOCRINOLOGY
    • 6.12     OTHER APPLICATIONS (ANESTHESIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY, AND ENT)
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     INDIA
      • 7.4.3     JAPAN
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     ACQUISITION
    • 8.3     EXPANSION
    • 8.4     AGREEMENTS
    • 8.5     SERVICE LAUNCH AND OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ABBVIE INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AENOVA HOLDING GMBH
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     FAREVA SA
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     LONZA GROUP LTD
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     PFIZER INC.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     PERMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     RECIPHARM AB
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     THERMO FISHER SCIENTIFIC INC
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, (2019-2027) ($MN)
      • TABLE 3     PATENT EXPIRY OF SMALL MOLECULE DRUGS, (2018 – 2025)
      • TABLE 4     ANDA APPROVALS, (2020 – 2021)
      • TABLE 5     AGREEMENTS/PARTNERSHIP, (2019 – 2021)
      • TABLE 6     ACQUISITION AND MERGER, (2019 – 2021)
      • TABLE 7     INVESTEMENTS, (2019 – 2021)
      • TABLE 8     API PRICING OF MAJOR SMALL MOLECULES
      • TABLE 9     GLOBAL PHARMACEUTICALS API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020)
      • TABLE 10     GLOBAL PHARMACEUTICAL API PRODUCTION, BY APPLICATION, (2019-2027) (TONS)
      • TABLE 11     GLOBAL SMALL MOLECULE API PRODUCTION, (2019 -2027) (METRIC TONS)
      • TABLE 12     GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
      • TABLE 13     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 14     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     API MANUFACTURING GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 16     API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 19     FDF MANUFACTURING GLOBAL MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
      • TABLE 20     FDF MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 22     INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 23     SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
      • TABLE 25     CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 27     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 28     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 29     CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     CARDIOVASCULAR DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 31     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 32     PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     GASTROINTESTINAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     ENDOCRINOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 38     OTHER APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 39     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 40     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 41     NORTH AMERICA API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 42     NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
      • TABLE 43     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
      • TABLE 44     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 45     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 46     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 47     EUROPE API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 48     EUROPE FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
      • TABLE 49     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
      • TABLE 50     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 51     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 52     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 53     APAC API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 54     APAC FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
      • TABLE 55     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
      • TABLE 56     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 57     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 58     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 59     ROW API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 60     ROW FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
      • TABLE 61     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
      • TABLE 62     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 63     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 64     ACQUISITION (2019-2021)
      • TABLE 65     EXPANSION (2019-2021)
      • TABLE 66     AGREEMENTS (2019-2021)
      • TABLE 67     SERVICE LAUNCH AND OTHERS (2019-2021)
      • TABLE 68     ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 69     ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 70     AENOVA HOLDING GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 71     CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 72     CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 73     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 74     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 75     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 76     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN)
      • TABLE 77     PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 78     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 79     RECIPHARM AB (PUBL): TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 80     RECIPHARM AB (PUBL): TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 81     RECIPHARM AB (PUBL): TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 82     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 83     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 84     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 85     WUXI APPTEC: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
      • TABLE 86     WUXI APPTEC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)

      LIST OF FIGURES

      • FIGURE 1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET
      • FIGURE 3     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 11     API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 12     FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     CONTRACT MANUFACTURING COMPANY CAPABILITIES
      • FIGURE 14     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, 2020 ($MN)
      • FIGURE 15     PATENT EXPIRY OF SMALL MOLECULES (2018-2025)
      • FIGURE 16     PATENT EXPIRY (2018-2025) AND ANDA APPROVALS (2020-2021), BY APPLICATION SHARE (%)
      • FIGURE 17     API DMF FILED BY COUNTRIES (2020) (NO’S)
      • FIGURE 18     API DMF FILED, BY COMPANY (2020) (NO’S)
      • FIGURE 19     FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE (2020)
      • FIGURE 20     FDA AND EMA APPROVED DRUGS AND FORMULATION TYPE (2020 – 2021)
      • FIGURE 21     FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO’S)
      • FIGURE 22     PHARMACEUTICAL API PRODUCTION BY APPLICATION (2020), (2019 – 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES)
      • FIGURE 23     GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2019 – 2027) (TONS), API CMO MARKET SHARE BY REGION (2020) (%)
      • FIGURE 24     INDIA V/S CHINA
      • FIGURE 25     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 26     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 27     API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
      • FIGURE 28     FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020 V/S 2027) (%)
      • FIGURE 29     SOLID DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE TYPE, (2020) (%)
      • FIGURE 30     SEMI-SOLID, LIQUID, AND GASEOUS DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE TYPE, (2020) (%)
      • FIGURE 31     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2020 V/S 2027) (%)
      • FIGURE 32     COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 33     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 34     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 35     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2020) (%)
      • FIGURE 36     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
      • FIGURE 37     NORTH AMERICA PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER BASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
      • FIGURE 38     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 39     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 40     U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 41     U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 42     REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 43     REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 44     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
      • FIGURE 45     EUROPE PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER PHASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
      • FIGURE 46     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 47     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 48     GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 49     GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 50     FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 51     FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 52     ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 53     ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 54     REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 55     REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 56     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
      • FIGURE 57     APAC PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE BY CUSTOMER BASE AND DOSAGE FORM (2020 V/S 2027) (%)
      • FIGURE 58     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 59     APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 60     CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 61     CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 62     INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 63     INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 64     JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 65     JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 66     REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 67     REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 68     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, BY PHASE (2020 V/S 2027) (%)
      • FIGURE 69     ROW PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET BY CUSTOMER BASE AND BY DOSAGE FORMS (2020 V/S 2027) (%)
      • FIGURE 70     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020) (%)
      • FIGURE 71     ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 72     BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 73     BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 74     REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 75     REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 76     MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
      • FIGURE 77     MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
      • FIGURE 78     KEY GROWTH STRATEGIES, (2019-2021)
      • FIGURE 79     SWOT: ABBVIE INC.
      • FIGURE 80     SWOT: AENOVA HOLDING GMBH
      • FIGURE 81     SWOT: CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
      • FIGURE 82     SWOT: CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED
      • FIGURE 83     SWOT: FAREVA
      • FIGURE 84     SWOT: LONZA GROUP
      • FIGURE 85     SWOT: PFIZER INC.
      • FIGURE 86     SWOT: PREMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
      • FIGURE 87     SWOT: RECIPHARM AB (PUBL)
      • FIGURE 88     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 89     SWOT: WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Aarthi Drugs Ltd
      • 2     AbbVie Inc.
      • 3     ACIC Pharmaceuticals Inc.
      • 4     ACS Dobfar
      • 5     Adare Pharmaceuticals, Inc.
      • 6     Aenova Group GmbH
      • 7     Aesica Pharmaceuticals Ltd
      • 8     Ajinomoto Bio-Pharma Services
      • 9     Akorn
      • 10     Alembic Pharmaceuticals Ltd
      • 11     Alkem Laboratories Ltd
      • 12     Almac Group
      • 13     Alpex Pharma S.A.
      • 14     Alpic Remedies Ltd
      • 15     Angelini Pharmaceuticals
      • 16     ANI Pharmaceuticals
      • 17     Anthem Biosciences Private Limited
      • 18     Aragen Life Sciences(GVK Biosciences Private Limited)
      • 19     Ardena Holding NV
      • 20     Artesan Pharma GmbH & Co. KG
      • 21     Athena Pharmaceutiques SAS
      • 22     August Bioservices LLC
      • 23     Aurobindo Pharma Limited
      • 24     Avara Pharmaceutical Services, Inc.
      • 25     Bachem Holding AG
      • 26     Bahrain Pharma
      • 27     Berkshire Sterile Manufacturing
      • 28     BioSig Technologies (ViralClear Pharmaceuticals)
      • 29     BioVectra Inc.
      • 30     BirgiMefar Group
      • 31      BSP Pharmaceuticals S.p.A
      • 32     Bushu Pharmaceuticals Ltd
      • 33     Cadila Pharmaceuticals Ltd
      • 34     Carlyle Group (Albany Molecular Research Inc.)
      • 35     Cascade Chemistry
      • 36     Celltrion Inc.
      • 37     Cerbios-Pharma SA
      • 38     ChemCon GmbH
      • 39     China Chemical & Pharmaceutical Co., Ltd
      • 40     China Resources Pharmaceutical Group Limited
      • 41     Cipla Limited
      • 42     CordenPharma International
      • 43     Cosmo Pharmaceuticals
      • 44     Daito Pharmaceutical Co.,Ltd.
      • 45     Debiopharm Group
      • 46     Delorbis Pharmaceuticals LTD
      • 47     Delpharm SAS
      • 48     Dishman (Dishman Carbogen Amcis Limited)
      • 49     Dottikon Exclusive Synthesis AG
      • 50     Dr. Reddy's Laboratories Ltd
      • 51     Eurofins Scientific
      • 52     EVER Pharma Holding Ges.m.b.H (EVER Neuro Pharma GmbH)
      • 53     Evonik Industries AG
      • 54     Fareva Group
      • 55     Flamma SpA
      • 56     Frontida BioPharm, Inc.
      • 57     GlaxoSmithKline plc
      • 58     Grand River Aseptic Manufacturing
      • 59     Group Pharmaceuticals Ltd
      • 60     Groupe Parima Inc.
      • 61     HBM pharma s.r.o
      • 62     Helsinn Holding S.A. (Helsinn Advanced Synthesis SA (HAS))
      • 63     Heraeus Holding GmbH
      • 64     Hetero Drugs Limited
      • 65     Hovione
      • 66     Hunan Huateng Pharmaceutical Co. Ltd.
      • 67     Injectalia Srl
      • 68     Jeil Pharmaceutical Co. Ltd
      • 69     Jubilant LifeSciences
      • 70     Kabi (Fresenius Kabi Contract Manufacturing)
      • 71     Kleos Pharma
      • 72     Kolmar Korea
      • 73     Laboratorios Farmacéuticos Rovi
      • 74     Lannett
      • 75     LGM Pharma, LLC
      • 76     Lonza Group
      • 77     Lotus Pharmaceutical Co., Ltd.
      • 78     LSNE Contract Manufacturing
      • 79     Mallinckrodt plc
      • 80     Marinopoulos Holding (Cyprus) Limited (Famar S.A.)
      • 81     Medicef Pharma Private Limited
      • 82     MedPharm Ltd.
      • 83     Merck KGaA
      • 84     Minakem
      • 85     Moleculin Biotech
      • 86     Nacto Pharma
      • 87     Neolpharma Pharmaceutical Group
      • 88     Neuland Laboratories Ltd.
      • 89     NextPharma Technologies Holding Limited
      • 90     Nipro Corporation
      • 91     Olon S.p.A.
      • 92     Otsuka Pharmaceutical Factory, Inc.
      • 93     Palladium Equity Partners
      • 94     Permira Funds (Cambrex Corporation)
      • 95     Perrigo Company plc
      • 96     Pfizer Inc.
      • 97     Pharmasynthese
      • 98     Pillar5 Pharma Inc.
      • 99     Piramal Pharma Solutions
      • 100     Polypeptide
      • 101     PROCOS S.p.A.
      • 102     Quotient Sciences
      • 103     Recipharm AB (publ)
      • 104     Regis Technologies
      • 105     Rottendorf Pharma
      • 106     Sai Life Sciences
      • 107     Samsung Biologics
      • 108     Sanofi S.A.
      • 109     ScinoPharm Taiwan Ltd.
      • 110     Seikagaku Corporation
      • 111     Seqens SAS
      • 112     Shilpa Medicare Limited
      • 113     Siegfried Holding AG
      • 114     SK Groups (SK Biopharmaceuticals)
      • 115     Solvias AG
      • 116     Sopharma Pharma Plc
      • 117     Sterling Pharma Solutions Limited
      • 118     Strides Pharma Science Ltd
      • 119     Sun Pharmaceutical Industries Ltd
      • 120     Supriya life science Ltd
      • 121     Takeda Pharmaceutical Company Limited
      • 122     Taro Pharmaceutical Industries Ltd
      • 123     Temad Co.
      • 124     Teva Pharmaceutical Industries Ltd.
      • 125     Thermofisher Scientific (Patheon N.V.)
      • 126     Unither Pharmaceuticals
      • 127     Upperton Pharma Solutions
      • 128     Viatris Inc. (Mylan N.V./Upjohn Pfizer Inc.)
      • 129     Wavelength Pharmaceuticals
      • 130     WuXi AppTec (WuXi STA pharmaceuticals)
      • 131     Zhejiang Huahai Pharmaceutical Co., Ltd
      • 132     Zhejiang Xianju Pharmaceutical Co.,Ltd.
      • 133      Zhejiang Hisun Pharmaceutical Co. Ltd.